Ohio High-Tech

Daniel Charles's article, "States Wrestle Over Measuring The Value Of High-Tech Development" (The Scientist, March 20, 1989, page 6) touches on some important questions for those sponsoring technology development initiatives. Unfortunately, the article misrepresented Ohio's approach to program assessment, and some of the statements I made on the matter were taken out of context. It is true that measurement of results from technology development programs is an important issue for many states and

Written byChristopher Coburn
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

It is true that measurement of results from technology development programs is an important issue for many states and to the business and scientific communities they serve. The long-term objectives and benefits of these initiatives make it difficult to show immediate economic payoffs, which are needed to generate the continual financing that is crucial to their success.

Charles's article leads one to believe that Ohio's Thomas Edison Program assessed its research centers totally on the basis of job creation (or only short-term results), but then decided to "pull away" from such an assessment strategy once the numbers were in. This could not be further from the truth. Job creation was only one of nine criteria that Ohio used to judge the centers' performance.

The nine criteria—taken as a whole—portray the Ohio centers' overall health and performance. The decision to focus on nine performance measures was made specifically so that Ohio ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies